Karyopharm Therapeutics Inc
(NAS:KPTI)
$
0.6763
-0.0238 (-3.4%)
Market Cap: 85.34 Mil
Enterprise Value: 149.08 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 68/100 Karyopharm Therapeutics Inc at Jefferies Healthcare Conference (Virtual) Transcript
Jun 02, 2021 / 01:30PM GMT
Release Date Price:
$9.26
(+1.20%)
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst
It's my pleasure that I'd like to welcome Richard Paulson, the CEO of Karyopharm. Thanks for joining us today, Richard.
Richard A. Paulson
Karyopharm Therapeutics Inc. - President, CEO & Director
Good morning, Maury. Great to be here.
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst
We're going to do a fireside chat. So maybe to start off, if you want to provide a 1-minute intro to Karyopharm, and maybe talk about some of the key catalysts at.
Richard A. Paulson
Karyopharm Therapeutics Inc. - President, CEO & Director
Sure. I think, Maury, I mean, as you know, and I think as many investors know, Karyopharm is now a fully commercial-stage organization, really founded in science and founded in development of the selective inhibition of nuclear export. And we are the leader in that with selinexor and our next-generation molecule eltanexor, with 3 approved
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot